Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Women and Infants Hospital of Rhode Island
432 participants
Jun 6, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity. The study will also have a long-term follow-up component (prospective cohort) including 346 participants from the parent trial to describe treatment continuation, treatment efficacy, patient direct costs and other secondary outcomes up to 5 years after treatment.
Eligibility
Inclusion Criteria7
- years or older
- report at least "quite a bit bothered" or worse by their UUI defined by response to OAB-q-SS item #8 "How bothered are you by urine loss associated with a strong desire to urinate?"
- are not and do not plan to become pregnant
- have persistent UUI defined as previous unsuccessful results after conservative and anticholinergic treatment, or are unable to tolerate or have contraindications to anticholinergics
- are currently not taking anticholinergics or are willing to stop medication for 3 weeks prior to enrollment.
- for participants reporting mixed urinary incontinence symptoms, participant must (a) have less bother from SUI than from UUI, defined as a response of "Not at all bothered" or only "a little bit bothered" by SUI on the Urogenital Distress Inventory item "Do you experience urine leakage related to physical activity? (walking, running, laughing, sneezing, coughing), and (b) SUI symptoms be stable (\> 3 months), and (c)participant does not desire additional treatment for SUI in the upcoming 3 months.
- Participants after unsuccessful neuromodulation trial can be eligible after a 4-week washout period.
Exclusion Criteria9
- clinical contraindication to beta-3 agonist or onabotulinumtoxinA
- prior therapeutic trial of either study treatment
- unevaluated hematuria, current or prior bladder malignancy
- surgically altered detrusor muscle
- prior pelvic radiation
- post-void residual \>150 mL in past 3 months
- neurogenic bladder
- pelvic floor surgery within the past 3 months
- anticipating pelvic surgery within primary outcome follow up period (3 months)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The beta-agonist oral medication will be prescribed and dose adjusted per usual care.
OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05806164